← All trials
NCT05990790
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 3, 2023
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- Aug 14, 2023
- Last posted
- Sep 6, 2023
- Enrollment
- 1332
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of ViennaLead sponsor
- Medical University of ViennaOverall official - principal investigator
- Medical University of ViennaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.